source
- Ipsen to acquire Memo Therapeutics and its kidney infection candidateFrench drugmaker Ipsen announced a new acquisition, agreeing to buy Memo Therapeutics along with its experimental kidney infection drug. This marks Ipsen's second transaction announced within a wee…
- Upcoming FDA decisions in Q3 2026 could signal agency flexibilityThe piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…